9:00am - 5:00pm

Our Opening Hours Mon. - Fri.


Call Us For Free Consultation




Dose Individualization of Pemetrexed – IMPROVE-II

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Dose Individualization of Pemetrexed – IMPROVE-II

Dose Individualization of Pemetrexed – IMPROVE-II

Estimated reading time: < 1 min

Condition: Non Small Cell Lung Cancer

Estimated Enrollment: 94

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Exposure (AUC),  The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing.,  Population Clearance (Cl), Population Intercompartmental Clearance (Q)

Interventions: Pemetrexed,


Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: September 1, 2021

Completion Date: September 1, 2021

Last  Posted Date: April 30, 2019

Location: Jeroen Bosch Hospital, ‘s-Hertogenbosch, Netherlands

Website Link: https://ClinicalTrials.gov/show/NCT03655821

Was this article helpful?
Dislike 0